Company Overview
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products in the United States, the United Kingdom, Northern Ireland, and Europe. The company was incorporated in 2014 and is based in Omer, Israel.
Why Investors Should Care
Revenue has grown at a 54.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $40.02M (+314.3% YoY); net profit $-15.85M.
- Trailing 12 Months Year-on-year growth — revenue +52.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 54.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 54.68% |
| 1 Year: | 52.00% |
Stock Price Performance
| 1 Year: | -66.58% |
| 6 Months: | -38.65% |
| 3 Months: | -41.84% |
| 1 Month: | -25.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)29.16 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 54.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 66.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PLSM Pulsenmore Ltd. PHARMA | 2.46 | -1.76 | $16.00M | 0.00% | -13.29% | -45.21% | 54.68% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 10.81M | 6.19M | 9.66M | 40.02M |
| Cost of Revenue | - | 5.69M | 3.99M | 6.08M | 6.34M |
| Gross Profit | - | 5.12M | 2.20M | 3.58M | 33.68M |
| Operating Expenses | - | 51.33M | 57.79M | 45.79M | 45.85M |
| Operating Income | - | -46.20M | -55.59M | -42.22M | -12.16M |
| EBITDA | - | -20.50M | -55.45M | -33.44M | -12.73M |
| Interest Expense | - | 323.00K | 586.00K | 502.00K | 315.00K |
| Pretax Income | - | -22.12M | -58.44M | -36.79M | -15.85M |
| Tax Provision | - | 0 | 127.00K | -56.00K | 1.00K |
| Net Income | - | -22.12M | -58.57M | -36.74M | -15.85M |
| Diluted EPS | - | -3.68 | -9.12 | -5.76 | -2.46 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 236.30M | 179.91M | 141.83M | 101.85M |
| Current Assets | - | 211.59M | 167.88M | 132.40M | 81.40M |
| Cash & Equivalents | - | 15.37M | 23.87M | 41.17M | 21.60M |
| Inventory | - | 14.25M | 23.69M | 23.09M | 6.59M |
| Receivables | - | 9.93M | 962.00K | 3.91M | 4.14M |
| Total Liabilities | - | 48.79M | 47.68M | 44.94M | 18.76M |
| Current Liabilities | - | 15.55M | 15.52M | 14.26M | 10.33M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 3.97M | 3.33M | 2.12M | 1.56M |
| Total Equity | - | 187.52M | 132.23M | 96.89M | 83.09M |
| Shares Outstanding | - | 6.24M | 6.25M | 6.27M | 6.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -27.52M | -49.66M | -41.46M | -32.88M |
| Investing Cash Flow | - | -124.55M | 56.71M | 58.58M | 13.85M |
| Financing Cash Flow | - | 50.97M | -1.14M | -1.56M | 4.00K |
| Capital Expenditure | - | -4.51M | -3.93M | -509.00K | -135.00K |
| Free Cash Flow | - | -32.03M | -53.59M | -41.97M | -33.01M |
| Net Change in Cash | - | -101.11M | 5.90M | 15.56M | -19.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 47.4% | 35.6% | 37.0% | 84.2% |
| Operating Margin % | - | -427.2% | -898.3% | -437.0% | -30.4% |
| Net Margin % | - | -204.5% | -946.5% | -380.3% | -39.6% |
| ROE % | - | -11.8% | -44.3% | -37.9% | -19.1% |
| ROCE % | - | -20.9% | -33.8% | -33.1% | -13.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Aquamarine Financial (cayman) Ltd | 5.21% | 338.54K | $751.56K |
| 2 | UBS Group AG | 0.32% | 21.02K | $46.66K |
| 3 | Mcguire Capital Advisors Inc | 0.01% | 500 | $1.11K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLSM
A newly registered system from Pulsenmore is designed for at-home IVF scans - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQaTNVWmVuM3UxclZFc1ZNZmFDdnoxY0VKTTdWODdQTk1DR3hRVE5qcGVvWENuRXBOekhpRVB1ME5yRGJIcXowMDlYZzllWWJkaC1SdGRaTlVQc3VGbDJ6MmJtQUJ6VTE4cGhUcFVqNDhMaWNEN3ZxX2J2SlFpcHEwOENPOTlpUEMxLUxpaH…
Pulsenmore (PLSM) surges as partnership news sparks buying in thinly traded shares | PLSM Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQLWJtVmdITm5XWExabTFjVEplSUpwb3hCRWFaV1I5LUE4WnlPMEdlUzBGb01MMG82UGdLcVVIQUNsa21yZUxOUFBrS1U0aTBwaWxBandTTi1zbEd5dkhvT191TW1uMm1EMGVlT2ZwVFhwODV6VzV6T0FIODRCbkVudGxpUURBR3ZYQWtHWW…
Pulsenmore Shares Soar After Joining Israel’s Healthcare AI Sandbox Programme (PLSM) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ3JJY3BNSmdQbnFjb0cyc2lsUkFPTDdGOEgwWTB5T056WjdubUNTM3o1S2hFQ24yRHJmTi1tTUNsVF9sT1ZGZHZhckpQU2dkUVV6V1BNaGh5Um51MmZScU8weUtFSkpYMTlHcWlqeWN6LUg5MEpaNUJtX0NLM1hBaXdqNVlzZE8zaTBTVD…
Why Did PLSM Stock Surge More Than 200% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNdWJuOWY1YzY4ODBLVHRnUnVCSU1Vc1dhbTBnd1FzRGdQZXdlWmVtREVwbEQxM2RQQThWQk5xTmIteHB4b09VcmdTX2JwNHptdHl6aTJHeG50b2w1OUswcVFYeVhlSUJBaGRaMVZ5TWxhRk1RbC1BWXhHR2pXZkdOZ1hKcnhUXzRJTzI0c0…
PLSM - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1CaXlVM3QtY05XVkIzcTRoRmlPZlh0YzVfN2djblAtU0l1V0UzR09oUTQ1a0lHT0lFMWl6NVBZb3RMejA5S0E?oc=5" target="_blank">PLSM</a> <font color="#6f6f6f">Finviz</font>…
Why Is Pulsenmore Stock Falling On Friday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNazFaVjdITC1GY1EwbnZsSmt3VGdBQjd6SkJJQ25PM3NyQll6VkYtZ1VjUGtBT1RMT21uZWJQbFNRZVZCQmVQQTQ2ZFFVWDBrNmtsNFNsdnprNXo2aWhLSzhtSjF6am1vMzdIYWNMNlhaTlhqT0lHRVMtcmNhMEpwelF4aHRxa0ZsQjNJLW…
PLSM — Frequently Asked Questions
What is the current share price of Pulsenmore Ltd. (PLSM)?
As of 2026-09-19 21:16 PDT, Pulsenmore Ltd. (PLSM) trades at $2.46 on NasdaqCM. Its 52-week range is $2.45 to $7.36.
What is the market capitalisation of PLSM?
Pulsenmore Ltd. (PLSM) has a market capitalisation of $16.00M on NasdaqCM.
What is the P/E ratio of PLSM?
PLSM trades at a trailing price-to-earnings (P/E) ratio of -1.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.19.
What is the return on equity (ROE) of PLSM?
PLSM has a return on equity (ROE) of -45.21%. Its return on capital employed (ROCE) is -13.29%.
Is PLSM a good stock to buy?
This page provides a data-driven analysis of Pulsenmore Ltd. (PLSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.